Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, USA.
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):485-503. doi: 10.1586/erp.12.29.
Autism spectrum disorders (ASDs) are characterized by impairments in social interaction, communication and behavioral functioning that can affect the health-related quality-of-life outcomes of the affected child and the family. ASDs have increased in prevalence, leading to a demand for improved understanding of the comparative effectiveness of different pharmacologic, behavioral, medical and alternative treatments for children as well as systems for providing services. This review describes outcome instruments that can be used for clinical, health services and cost-effectiveness applications. There is a pressing need to identify the most appropriate instruments for measuring health-related quality-of-life outcomes in this population. Studies evaluating the cost-effectiveness of interventions or treatments for children with ASDs using the cost per quality-adjusted life year metric are lacking. Researchers have the potential to contribute greatly to the field of autism by quantifying outcomes that can inform optimal treatment strategies.
自闭症谱系障碍（ASD）的特征是社交互动、沟通和行为功能受损，这可能会影响受影响儿童及其家庭的与健康相关的生活质量结果。ASD 的患病率有所增加，这导致人们对不同药物治疗、行为治疗、医疗和替代治疗以及提供服务的系统的相对有效性有了更高的要求。本综述介绍了可用于临床、医疗服务和成本效益应用的结果评估工具。目前迫切需要确定最适合测量该人群健康相关生活质量结果的工具。使用质量调整生命年指标衡量 ASD 儿童干预或治疗成本效益的研究还很缺乏。研究人员通过量化可以为最佳治疗策略提供信息的结果，有潜力为自闭症领域做出重大贡献。
